Related by context. Frequent words. (Click for all words.) 71 VEGFR2 inhibitor 69 candidate AP# 69 Emergent marketed 68 R sorafenib tablets 68 YOUR LOCAL ANIMAL SHELTER 67 MKC# MT 67 multi kinase inhibitor 66 Initiates Phase II 66 Completes Patient Enrollment 66 sorafenib tablets 65 MKC# 65 Meets Primary Endpoint 65 signal detection CTSD 65 novel orally administered 65 huC# DM4 65 Sapacitabine 65 fibrosis IPF 65 ® bortezomib 65 By MOISEKAPENDA BOWER 65 PNP inhibitor 65 optical biosensors 65 Belimumab 64 liposomal formulation 64 By HARVEY SIMPSON 64 By Thomas Gryta 64 Sodium oxybate 64 oral antiviral 64 oncolytic virus therapies 64 topical non steroidal 64 non nucleoside polymerase 64 epothilones 64 Panzem R 63 POGO ™ 63 BY JIM DeROGATIS 63 Receives Orphan Drug Designation 63 By DANIE HARRELSON 63 proteasome inhibitor 63 Romidepsin 63 HIV protease inhibitor Lexiva 63 By Katy Burne 63 Presents Positive 63 Reliable UPS Mgmt 63 By MIKE McKIBBIN 63 By MIKE SACCONE 63 CCX# 63 By RICK KRETZSCHMAR 63 overactive bladder AA# 63 direct Factor Xa 63 Antigen Express website 63 CD#.# DOES NOT ENDORSE 63 2 methoxyestradiol 63 HOW LONG WAS 63 By BEVERLY CORBELL 63 Tesetaxel 63 Regulatory Disclosure 63 www.combinatorx.com 63 % #F# #v.jsn 63 addressing idiopathic pulmonary 63 Lenor ® Iams 63 Copegus R 62 Kinase Inhibitor 62 Methylnaltrexone 62 Anti Tumor 62 Amgen discovers develops 62 refractory chronic lymphocytic 62 Golimumab 62 TRISCUIT crackers 62 metastatic colorectal 62 XL# XL# XL# XL# 62 peripherally acting 62 Vytorin combines 62 Omacetaxine 62 HGS ETR2 62 Epratuzumab 62 PET FROM 62 NOT THIS WEBSITE 61 includes iFinix RealTime 61 hepatitis C lupus 61 Completes Enrollment 61 Dapagliflozin 61 BY STEPHANIE A. WILKEN 61 Lipid Polymer Micelle LPM 61 HCV protease inhibitor 61 By Riva Froymovich 61 trastuzumab DM1 T DM1 61 Study Evaluating 61 BY WILLIAM ROLLER 61 MGCD# MGCD# [001] 61 Pazopanib 61 Mipomersen 61 Entereg R 61 By PATRICK BAHR 61 developing Zerenex TM 61 JAK inhibitor 61 targeting CD# 61 Sie lesen Finanznachrichten und 61 inhaled formulation 61 systemically administered 61 MATTERS DISCUSSED IN 61 targeted immunotherapies 61 SAR# [002]